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Antiretroviral therapy (ART) has significantly improved the quality of life
of Human Immunodeficiency Virus (HIV) patients; but adverse side
effects and poor patient compliance to lifelong daily pills remain major
challenges. To this end, the need for long acting (LA) therapies that can
improve treatment adherence, positively affect drug resistance patterns
in addition to limiting drug toxicities cannot be overstated. Tenofovir
alafenamide (TAF), a nucleotide reverse transcriptase inhibitor of HIV
infection and prodrug of tenofovir (TFV), is characterized by potent
antiretroviral activities and high genetic barrier to viral resistance
making it a suitable candidate for long-acting antiretroviral therapy.
However, the inherent physicochemical features of TAF that includes
high water solubility and susceptibility to degradation in aqueous
buffers has limited its transformation into long-acting sustained release
formulations. With these limitations in mind, this work sought to
produce a stable TFV prodrug that would facilitate development of a
long-acting formulation without compromising on TAF’s antiretroviral
activity and safety profile. A lipophilic and hydrophobic prodrug of TFV
(M1TFV) was therefore developed through chemical synthesis making
it possible to formulate the drug as a stable aqueous nanosuspension
to improve upon drug dissolution. The aqueous poloxamer stabilized
TFV prodrug nanosuspension (NM1TFV) was characterized for
physicochemical properties, chemical stability, cellular drug uptake and
retention. The average particle size of the nanoparticles was 220-270
nm with a polydispersity index of <0.5, suggesting uniform particle size
distribution within the formulation. Compared to TAF, the synthesized
M1TFV prodrug demonstrated improved prodrug stability in water and
enhanced intracellular drug uptake in monocyte derived macrophages
and was also efficiently converted into the active metabolite (TFV-DP)
that competitively inhibits the activity of HIV reverse transcriptase
enzyme to stop the virus from replicating. These results are a major
step towards producing a novel long acting tenofovir formulation that
could potentially facilitate treatment and prevention of HIV infection.
Results
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(1) M1TFV was synthesized and its physicochemical properties were characterized.
(2) Surfactant stabilized M1TFV nanoparticles exhibited stable particle sizes and narrow
polydispersity indices
(3) NM1TFV demonstrated enhanced MDM drug uptake and retention compared to TAF.
Future Studies
(1) Anti-retroviral efficacy studies in MDM and CD4+ T cells to determine whether the prodrug
formulations would lead to sustained efficacy.
(2) In vivo pharmacokinetics, biodistribution and drug release studies.
(3) In vivo pharmacodynamic studies.
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Methods
M1TFV Synthesis and Characterization: The monophosphorylated
prodrug of TFV was synthesized through a modified ProTide
approach(1). Successful prodrug synthesis was confirmed using
nuclear magnetic resonance (NMR) and mass spectroscopy.
Nanocrystal Development: The hydrophobic and lipophilic M1TFV
prodrug was nanoformulated in an aqueous buffer by high pressure
homogenization using poloxamer 407 (P407) as the stabilizing
surfactant.
Drug uptake and Retention in MDM : Human monocyte derived
macrophages (MDM) were obtained by differentiating primary
monocytes with macrophage colony stimulating factor. For drug uptake
studies, MDM were treated with 10 µM of M1TFV and collected at
various time intervals over 24 hours for intracellular drug quantitation
by UPLC-UV/Vis. For drug retention studies, MDM were treated with 10
µM of drug for 8 hours, then washed twice with phosphate buffered
saline and cultured in media without drug until days of collection and
analyses by UPLC-UV/Vis. Since the active form of the nucleotide
analog is a diphosphate, both uptake and retention samples were
analyzed for TFV-DP levels.
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Figure 1. (a) Synthesis scheme for M1TFV. (b) 1H NMR spectra of M1TFV was acquired in deuterated chloroform (c) 31P NMR
spectrum of M1TFV representing the two diastereomers (RP and SP) of the prodrug. (d) Mass spectrometric analyses (Bruker






Figure 3. (a) Evaluation of mitochondrial activity demonstrated that NM1TFV exerted no adverse
effects to cell viability at 200uM of drug or less.(b) Following 10 μM treatments of NM1TFV or
NTAF, intracellular prodrug (left panel in b) and TFV-DP (right panel) concentrations in MDM were
measured over an 8hr period. Prodrug levels for NM1TFV were significantly greater than for NTAF.
However, TAF treatment results in faster prodrug conversion to TFV-DP (right panel), compared to
NM1TFV. (c) Concentrations of prodrug (left panel) and TFV-DP (right panel) following 10 μM
treatments of NM1TFV or TAF were determined in MDM over 30-day period.
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Figure 2. (a) Schematic representation of nanoformulation of M1TFV. The formulation was produced by high pressure
homogenization using poloxamer as the surfactant. (b) M1TFV nanoparticles were characterized for particle size, homogeneity (PDI)
and surface charge (zeta potential) by dynamic light scattering on a Malvern Zetasizer Nano-ZS.
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